Market Cap : 126.11 B | Enterprise Value : 140.18 B | PE Ratio : 25.44 | PB Ratio : 2.39 |
---|
NYSE:MDT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NYSE:MDT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Medtronic's annualized Net Income for the quarter that ended in Apr. 2022 was $5,940 Mil. Medtronic's average Total Assets over the quarter that ended in Apr. 2022 was $91,393 Mil. Therefore, Medtronic's annualized ROA % for the quarter that ended in Apr. 2022 was 6.50%.
The historical rank and industry rank for Medtronic's ROA % or its related term are showing as below:
During the past 13 years, Medtronic's highest ROA % was 10.24%. The lowest was 3.25%. And the median was 4.58%.
The historical data trend for Medtronic's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Medtronic's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Medtronic's ROA % distribution charts can be found below:
* The bar in red indicates where Medtronic's ROA % falls into.
Medtronic's annualized ROA % for the fiscal year that ended in Apr. 2022 is calculated as:
ROA % | = | Net Income (A: Apr. 2022 ) | / | ( (Total Assets (A: Apr. 2021 ) | + | Total Assets (A: Apr. 2022 )) | / count ) |
= | 5039 | / | ( (93083 | + | 90981) | / 2 ) | |
= | 5039 | / | 92032 | ||||
= | 5.48 % |
Medtronic's annualized ROA % for the quarter that ended in Apr. 2022 is calculated as:
ROA % | = | Net Income (Q: Apr. 2022 ) | / | ( (Total Assets (Q: Jan. 2022 ) | + | Total Assets (Q: Apr. 2022 )) | / count ) |
= | 5940 | / | ( (91804 | + | 90981) | / 2 ) | |
= | 5940 | / | 91392.5 | ||||
= | 6.50 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Apr. 2022) net income data. ROA % is displayed in the 30-year financial page.
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bankÂ’s ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
ROA % | (Q: Apr. 2022 ) | ||
= | Net Income | / | Total Assets |
= | 5940 | / | 91392.5 |
= | (Net Income / Revenue) | * | (Revenue / Total Assets) |
= | (5940 / 32356) | * | (32356 / 91392.5) |
= | Net Margin % | * | Asset Turnover |
= | 18.36 % | * | 0.354 |
= | 6.50 % |
Note: The Net Income data used here is four times the quarterly (Apr. 2022) net income data. The Revenue data used here is four times the quarterly (Apr. 2022) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Thank you for viewing the detailed overview of Medtronic's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.
Fong Ivan K | officer: EVP GENERAL COUNSEL & SECR | 3M CENTER ST. PAUL MN 55144-1000 |
Kirk Jennifer M | officer: Chief Accounting Officer | 5 GREENWAY PLAZA SUITE 110 HOUSTON TX 77046 |
Lofton Kevin E | director | GILEAD SCIENCES, INC. 333 LAKESIDE DRIVE FOSTER CITY CA 94404 |
Wall Brett A. | officer: EVP & Group Pres Restora Thera | 710 MEDTRONIC PARKWAY LC300 MINNEAPOLIS MN 55432 |
Salmon Sean | officer: EVP & Group President Diabetes | MEDTRONIC PLC, 710 MEDTRONIC PARKWAY LC300 MINNEAPOLIS MN 55432 |
Goldsmith Andrea Jo | director | 1220 AUGUSTA DRIVE SUITE 600 HOUSTON TX 77057 |
Liddicoat John R | officer: EVP & President of Americas | MEDTRONIC PLC 710 MEDTRONIC PKWY, MS LC300 MINNEAPOLIS MN 55432 |
White Robert John | officer: EVP & President MITG | MEDTRONIC PLC 710 MEDTRONIC PKWY MS LC300 MINNEAPOLIS MN 55432 |
Parkhill Karen L | officer: EVP & Chief Financial Officer | 1717 MAIN STREET, MC 6402 DALLAS TX 75201 |
Reddy Preetha | director | APOLLO HOSPITALS 21 GREAMS LN, OFF GREAMS RD CHENNAI K7 600006 |
Ellis Gary Lee | officer: EVP & Chief Financial Officer | THE TORO COMPANY 8111 LYNDALE AVENUE SOUTH BLOOMINGTON MN 55420 |
Hanson Bryan C | officer: EVP AND PRESIDENT, COVIDIEN | ZIMMER BIOMET HOLDINGS 345 E. MAIN STREET WARSAW IN 46580 |
Hakami Hooman | officer: EVP & Group President Diabetes | 710 MEDTRONIC PKWY MSLC300 MINNEAPOLIS MN 55432 |
Oconnell Christopher J | officer: See Remarks | MEDTRONIC, INC. 710 MEDTRONIC PKWY MINNEAPOLIS MN 55432 |
Lenehan James T | director | C/O MEDTRONIC INC 710 MEDTRONIC PKWY MS LC300 MINNEAPOLIS MN 55432 |
Other Sources
By Fool 2022-03-09
By Zacks 2022-04-05
By Zacks 2022-03-28
By Zacks 2022-03-24
By Zacks 2022-03-23
By Zacks 2022-04-05
By Zacks 2022-02-22
By tipranks.com 2022-03-06
By Seekingalpha 2022-02-22
By Zacks 2022-03-24
By Zacks 2022-02-23
By Zacks 2022-03-10
By Zacks 2022-03-07
By Fool 2022-03-02